• Truist Financial sets a price target of $30 for NYSE:RCUS, indicating a potential upside of 34.74%.
• The discontinuation of the Phase 3 STAR-221 study with Gilead Sciences, Inc. (NASDAQ:GILD) impacts investor sentiment and stock performance.
• Arcus Biosciences shifts focus to Casdatifan and its emerging inflammation and immunology portfolio following the study's halt.

Arcus Biosciences, Inc. (NYSE:RCUS) is a biopharmaceutical company dedicated to developing innovative cancer therapies. Recently, Truist Financial set a price target of $30 for RCUS, suggesting a potential upside of 34.74% from its current trading price of $22.27. However, recent developments have impacted the stock's performance.

Arcus announced the discontinuation of its Phase 3 STAR-221 study, conducted with Gilead Sciences, Inc. (NASDAQ:GILD). The Independent Data Monitoring Committee recommended halting the study after an interim analysis showed no improvement in overall survival with the domvanalimab-based combination compared to nivolumab plus chemotherapy. Despite similar safety profiles, this decision has affected investor sentiment.

Following the announcement, RCUS stock experienced a significant decline, reversing an eight-month winning streak with gains of nearly 300%. The stock dropped to $21.77, a decrease of 13.42%, or $3.38, from its previous value. During the trading day, it fluctuated between $20.35 and $24, reflecting market volatility.

Arcus is now shifting its focus to its research and development investment in Casdatifan and its emerging inflammation and immunology portfolio. The company's market capitalization stands at approximately $2.35 billion, with a trading volume of 5,619,062 shares today. Despite recent setbacks, Arcus remains committed to advancing its pipeline and exploring new opportunities.